Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLOWTUSS vs AMMONIUM CHLORIDE IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
FLOWTUSS (guaifenesin) is an expectorant that increases respiratory tract fluid secretions, reducing mucus viscosity and facilitating clearance.
Ammonium chloride is an acidifying agent that provides chloride ions and ammonium ions. The ammonium ion is converted to urea in the liver, releasing hydrogen ions, which leads to metabolic acidosis. It also directly stimulates the respiratory center and promotes diuresis by increasing the osmotic load.
Relief of productive cough associated with respiratory tract infections,Chronic obstructive pulmonary disease (COPD) exacerbations,Cystic fibrosis (off-label)
Treatment of metabolic alkalosis,Urinary acidification to facilitate excretion of weak bases in poisoning,Hypochloremic states
10 mg orally every 4-6 hours as needed for cough; maximum 60 mg/day.
For metabolic alkalosis: 1-2 g intravenously every 6-12 hours as needed; maximum 6 g/day. For hypochloremic states: 1-2 g orally or intravenously 2-3 times daily.
Terminal elimination half-life is 4–6 hours in adults with normal renal function; prolonged to 8–12 hours in moderate renal impairment (Cr Cl 30–50 m L/min).
Terminal elimination half-life is approximately 2-4 hours in adults with normal hepatic and renal function. This reflects the rapid conversion of ammonium to urea in the liver and subsequent renal clearance. Half-life may be prolonged in hepatic or renal impairment.
Hepatic metabolism via oxidation and demethylation; primarily excreted renally as metabolites.
Metabolized primarily in the liver via the urea cycle; ammonium ion is converted to urea, releasing hydrogen ions. The chloride ion is excreted renally.
Renal elimination of unchanged drug accounts for 60–70%; hepatic metabolism (30–40%) with fecal excretion of metabolites via bile (20–25%) and urine (10–15%).
Renal: >99% as ammonium and chloride ions. The kidney converts ammonia to urea, which is excreted in urine. Fecal and biliary elimination are negligible.
85–90% bound to albumin and alpha-1-acid glycoprotein.
<1% bound to plasma proteins. Ammonium ions are primarily free in plasma.
1.5–2.0 L/kg; indicates extensive tissue distribution (e.g., lungs, liver).
Approximately 0.2-0.3 L/kg, reflecting distribution mainly in extracellular fluid. Ammonium ions do not significantly penetrate cells under normal conditions.
Oral: 75–85% (first-pass metabolism accounts for 15–25% loss).
Oral: ~100% absorbed from the gastrointestinal tract, though first-pass hepatic metabolism (urea cycle) limits systemic availability of intact ammonium. Intravenous: 100% bioavailable.
e GFR 30-60 m L/min: 5 mg every 6 hours; e GFR <30 m L/min: 5 mg every 8 hours.
Contraindicated in severe renal impairment (GFR <30 m L/min). For GFR 30-50 m L/min: reduce dose by 50% and monitor serum chloride and ammonia. For GFR >50 m L/min: no adjustment necessary.
Child-Pugh Class B: 5 mg every 6 hours; Child-Pugh Class C: 2.5 mg every 8 hours.
Contraindicated in severe hepatic insufficiency (Child-Pugh class C). For Child-Pugh class B: use with caution, reduce dose by 50% and monitor ammonia levels. For Child-Pugh class A: no adjustment necessary.
Children 2-6 years: 2.5 mg orally every 6 hours; 6-12 years: 5 mg orally every 6 hours; >12 years: same as adult.
For metabolic alkalosis: 50-100 mg/kg intravenously every 6-8 hours; maximum 2 g/day. For hypochloremic states: 75 mg/kg/day orally in divided doses.
Initial dose 5 mg every 6 hours; increase cautiously due to increased risk of dizziness and sedation.
Start at lower end of dosing range (e.g., 1 g intravenously every 12 hours) due to age-related decline in renal function; monitor serum electrolytes and renal function closely.
None.
None
Avoid use with persistent or chronic cough (e.g., smoking, asthma, COPD) unless directed by a physician. Use caution in patients with renal impairment.
Use with caution in patients with hepatic impairment (risk of ammonia toxicity), renal dysfunction, or respiratory acidosis. Monitor acid-base status, serum chloride, and ammonia levels. Avoid rapid infusion to prevent severe acidosis. Not for use in severe hepatic insufficiency.
Hypersensitivity to guaifenesin or any component; concurrent use with other expectorants.
Severe hepatic insufficiency; severe renal failure with oliguria or anuria; primary respiratory acidosis; hypokalemia (due to risk of exacerbating potassium loss); hypersensitivity to ammonium chloride.
No specific food interactions. Alcohol may increase CNS depressant effects (dizziness, sedation).
Avoid excessive dietary intake of chloride-rich foods (e.g., table salt, processed foods) as it may affect treatment. No specific food restrictions, but maintain balanced diet as advised by physician.
FLOWTUSS contains guaifenesin and dextromethorphan. Guaifenesin is FDA pregnancy category C; animal studies show fetal abnormalities at high doses, but human data insufficient. Dextromethorphan is category C; limited human studies show no clear teratogenic risk, but high doses may cause fetal toxicity. Avoid in first trimester; use only if benefit outweighs risk in second and third trimesters.
FDA Pregnancy Category C. Ammonium chloride crosses the placenta. First trimester: insufficient human data; animal studies not available; theoretical risk of fetal acidosis if maternal acidosis induced. Second/third trimester: may cause fetal acidosis, electrolyte disturbances, and potential for fetal harm if maternal overdose or pre-existing acidosis.
Guaifenesin and dextromethorphan are excreted in breast milk in low amounts. M/P ratio not established for either. Use with caution; monitor infant for sedation or respiratory depression.
No human data on excretion in breast milk. M/P ratio unknown. Caution advised; consider risk of infant acidosis and ammonia toxicity if exposed.
No standard dose adjustment recommended during pregnancy. Use lowest effective dose for shortest duration. Consider pharmacokinetic changes in pregnancy (increased clearance of dextromethorphan may require higher doses for efficacy, but safety limits apply).
No established dose adjustment for pregnancy. Decreased GI motility and increased plasma volume may alter absorption and distribution; however, dosing should be guided by clinical response and frequent monitoring of acid-base and electrolyte status. Avoid overdosing to prevent maternal and fetal acidosis.
FLOWTUSS (guaifenesin) is an expectorant that increases respiratory tract fluid secretion, reducing mucus viscosity. Onset of action is 30-60 minutes. Maximum effect requires adequate hydration (8-10 glasses of water daily). Not recommended for chronic cough due to smoking, asthma, or emphysema. Avoid use in patients with persistent cough lasting >1 week or accompanied by fever, rash, or headache. May cause dizziness; caution when driving.
Ammonium chloride is used to treat severe metabolic alkalosis by providing chloride ions and generating mild metabolic acidosis. Monitor serum chloride, bicarbonate, and p H closely during infusion. Avoid in patients with severe hepatic impairment or renal failure. Infusion may cause local irritation; ensure proper IV access.
Drink plenty of water to help loosen mucus.,Do not take more than 6 doses in 24 hours.,Discontinue and consult doctor if cough persists >7 days or if fever, rash, or headache develop.,Avoid alcohol; may increase dizziness.,Do not use for chronic cough from smoking or asthma without medical advice.
This medication is used to correct an acid-base imbalance in your blood.,It will be given intravenously (IV) by a healthcare professional.,Report any burning, pain, or redness at the IV site immediately.,Do not consume large amounts of salt or salty foods unless directed.,Tell your doctor if you have liver or kidney disease.
No interactions on record
"Ammonium chloride, an acidifying agent, reduces urinary pH, which increases the renal clearance of lisdexamfetamine and its active metabolite d-amphetamine. This accelerated elimination leads to decreased systemic exposure and potentially diminished therapeutic efficacy of lisdexamfetamine. Clinically, patients may experience reduced symptom control for ADHD or binge eating disorder, requiring dose adjustments or alternative therapies."
"Sufentanil, a potent opioid analgesic, may increase renal excretion of ammonium chloride by promoting diuresis through opioid-induced release of antidiuretic hormone (ADH) and subsequent water reabsorption, leading to dilutional acidosis and enhanced ammonium excretion. This interaction can result in reduced serum ammonium levels and decreased efficacy of ammonium chloride as an acidifying agent, potentially compromising its therapeutic effect in metabolic alkalosis or urinary tract infections. Clinical outcomes may include incomplete correction of metabolic alkalosis or reduced antimicrobial activity of ammonium chloride in the urine."
"Ammonium chloride acidifies the urine, which increases the renal excretion of amphetamine by favoring its ionized form in the tubular lumen, thereby reducing its reabsorption. This leads to a decreased serum concentration of amphetamine and potentially diminished therapeutic efficacy. Clinically, patients may experience reduced mood-elevating or stimulant effects, requiring dose adjustment."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLOWTUSS vs AMMONIUM CHLORIDE IN PLASTIC CONTAINER, answered by our medical review team.
FLOWTUSS is a Expectorant that works by FLOWTUSS (guaifenesin) is an expectorant that increases respiratory tract fluid secretions, reducing mucus viscosity and facilitating clearance.. AMMONIUM CHLORIDE IN PLASTIC CONTAINER is a Expectorant/Systemic Acidifier that works by Ammonium chloride is an acidifying agent that provides chloride ions and ammonium ions. The ammonium ion is converted to urea in the liver, releasing hydrogen ions, which leads to metabolic acidosis. It also directly stimulates the respiratory center and promotes diuresis by increasing the osmotic load.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLOWTUSS and AMMONIUM CHLORIDE IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLOWTUSS is: 10 mg orally every 4-6 hours as needed for cough; maximum 60 mg/day.. The standard adult dose of AMMONIUM CHLORIDE IN PLASTIC CONTAINER is: For metabolic alkalosis: 1-2 g intravenously every 6-12 hours as needed; maximum 6 g/day. For hypochloremic states: 1-2 g orally or intravenously 2-3 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLOWTUSS and AMMONIUM CHLORIDE IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLOWTUSS is classified as Category C. FLOWTUSS contains guaifenesin and dextromethorphan. Guaifenesin is FDA pregnancy category C; animal studies show fetal abnormalities at high doses, but human data insufficient. Dex. AMMONIUM CHLORIDE IN PLASTIC CONTAINER is classified as Category C. FDA Pregnancy Category C. Ammonium chloride crosses the placenta. First trimester: insufficient human data; animal studies not available; theoretical risk of fetal acidosis if mate. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.